Future research should focus on elucidating the specific pathways through which AMPK modulates immune metabolism during sepsis and developing biomarkers to guide the use of AMPK-targeted therapies in overcoming immunometabolic paralysis (44). This evidence concerns the gene PRKAA1 and Sepsis.